Our founder and partner, Robert L. Buchanan was sworn in for admission to the Bar of the Supreme Court of the United States on Friday, March 15, 2023.
Robert…
Friday, 15th March saw the final day of Ventac Partners' week-long “build a biotech” course at Norwegian University of Science and Technology (NTNU) in…
Friday 24th March saw the last day of Ventac Partners week-long “build a biotech” course at NTNU, Trondheim, Norway with some entertaining and successful…
Today marks the start of the 20th edition of Ventac Partners’ “build a biotech” course at NTNU, now in its 19th year. Over 80 Master’s & PhD students will…
Kinarus Secures CHF 57 Million Capital Commitment from Global Emerging Markets (GEM). Ventac Partners is delighted to have supported the company in achieving…
Cenexum Technologies, a portfolio company of Ventac Partners, has received the prestigious Innofounder Grant from Innovation Fund Denmark. It will allow…
Orbit Genomics was awarded a $2 million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer test. This test will be the second…
Orbit Genomics, a Ventac Partners portfolio company, has been selected for the inaugural cohort of startups of the CancerX Accelerator program. For more…
We are very happy to see Ventac portfolio company Regenesance BV (dba Complement Pharma BV) publish a research article with Alexion, AstraZeneca Rare Disease…
We are delighted to see our portfolio company, RORA Biologics complete its exclusive license agreement with Case Western Reserve University (Cleveland, Ohio,…
Ventac Partners portfolio company Orbit Genomics announced it has received $3 million in funding to launch its first product, OrbiSeq™ – L, a lung cancer…
APIM Therapeutics announced today that a Phase II Investigator Initiated Study (IIS) of ATX-101 will begin enrolling patients with sarcoma at Columbia…
APIM Therapeutics announced today that the first patient has been treated with ATX-101 in the company's phase I/II ovarian cancer study. The clinical study…
Ventac portfolio company RhoVac AB report positive 3-year follow-up results from a Phase I/IIa study in prostate cancer. The company is a clinical stage…
APIM Therapeutics has presented a poster summarizing results from its on-going first-in-human clinical study with ATX-101 in advanced cancer patients during…
RhoVac AB announced today, 9th June 2021, that it has received full approvals to initiate a follow-up study of the patients that took part in the company’s…
APIM Therapeutics announced today completion of a private placement round by existing and new investors. With the proceeds from the private placement, the…
APIM Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application (IND) for a Phase 1b/2a…
RhoVac AB announced on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company's clinical phase IIb study in prostate cancer, a…
Ventac Partners announces the launch of Ambulero, a Miami-based spin-out of the University of Miami Miller Medical School focused on new gene and cell therapy…
Ventac Partners portfolio company Idogen announced that the company’s technology platform for tolerogenic dendritic cell generation has been successfully…
Ventac Partners portfolio company RhoVac announced that the first patient has been screened for the company's clinical phase IIb study in prostate cancer, a…
Ventac Partners portfolio company RhoVac reports it has been granted 2.5 million euro from Horizon 2020. For more information, please follow this link.
Ventac Partners portfolio company Idogen reports it has successfully established a novel method for the company's cell therapy. For more information, please…
Ventac Partners portfolio company RhoVac AB receives approval to start clinical phase IIb study in Denmark. For more information, please follow this link.
Ventac Partners portfolio company RhoVac announces that all patients completed the follow-up phase of the clinical phase I / II study. For more information,…
Our partner Dede Willis will be presenting the Harry William Lee Porth Distinguished Lecture at Missouri University of Science and Technology. Her talk is…
Ventac Partners will sit on an investor panel at the LSX World Congress USA to be held this September in Boston. Please reach out to partners Robert Buchanan…
RhoVac AB will be participating in a series of meetings during May-August 2021 including Aktiedagen Göteborg 17 May (digital) and BioStock’s LifeScience Spring…
RhoVac AB will be participating in a series of meetings during May-August 2021 including Aktiedagen Göteborg 17 May (digital) and BioStock’s LifeScience Spring…
The 17th edition of Ventac Partners' week-long “Build a Biotech” course at the Norwegian University of Science and Technology (NTNU) took place in mid-March. A…
APIM Therapeutics will be participating at the virtual Biopharma CxO Roundtable entitled: “Clinical trial acceleration — 500 days faster from start to finish”…
The 16th edition of Ventac Partners' week-long “Build a Biotech” course at the Norwegian University of Science and Technology (NTNU) has taken place this…
Ventac Partners M. Oerum, Scott Woodward, Dede Willis and Randy Berholtz will be attending the 38th Annual J.P. Morgan Healthcare Conference, San Francisco,…
